Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization - PubMed (original) (raw)
Clinical Trial
doi: 10.1007/BF03324024.
Affiliations
- PMID: 1764497
- DOI: 10.1007/BF03324024
Clinical Trial
Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization
A Amery et al. Aging (Milano). 1991 Sep.
Abstract
The Syst-Eur Trial is a concerted action of the European Community's Medical and Health Research Programme. The trial is carried out in consultation with the World Health Organization, the International Society of Hypertension, the European Society of Hypertension and the World Hypertension League. This article describes the objectives and the protocol of Syst-Eur, a multicentre trial designed by the European Working Party on High Blood Pressure in the Elderly (EWPHE), to test the hypothesis that antihypertensive treatment of elderly patients with isolated systolic hypertension results in a significant change in stroke morbidity and mortality. Secondary endpoints include cardiovascular events, such as myocardial infarction and congestive heart failure. To be eligible patients must be at least 60 years old and have a systolic blood pressure averaging 160-219 mmHg with a diastolic pressure less than 95 mmHg. Patients must give their informed consent and be free of major cardiovascular and non-cardiovascular diseases at entry. The patients are randomized to active treatment or placebo. Active treatment consists of nitrendipine (10-40 mg/day), combined with enalapril (5-20 mg/day) and hydrochlorothiazide (12.5-25 mg/day), as necessary. The patients of the control group receive matching placebos. The drugs (or matching placebos) are stepwise titrated and combined in order to reduce systolic blood pressure by 20 mmHg at least to a level below 150 mmHg. Morbidity and mortality are monitored to enable an intention-to-treat and per-protocol comparison of the outcome in the 2 treatment groups. A one-year pilot trial (1989) showed that the protocol is practicable. The Ethics Committee therefore decided to start the definite study (1990), in which randomized patients will be followed for 5 years. Recruitment of new centres and of the required 3,000 patients will last 3 years (until 1993).
Similar articles
- Trials in elderly patients with isolated systolic hypertension.
Staessen J, Guo C, Celis H, Fagard R, Thijs L, Amery A. Staessen J, et al. Chin Med J (Engl). 1992 May;105(5):364-8. Chin Med J (Engl). 1992. PMID: 1499364 Clinical Trial. - Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Staessen JA, et al. Lancet. 1997 Sep 13;350(9080):757-64. doi: 10.1016/s0140-6736(97)05381-6. Lancet. 1997. PMID: 9297994 Clinical Trial. - Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Fagard RH, Staessen JA. Fagard RH, et al. Clin Exp Hypertens. 1999 Jul-Aug;21(5-6):491-7. doi: 10.3109/10641969909060982. Clin Exp Hypertens. 1999. PMID: 10423075 Clinical Trial. - Risk reduction associated with lowering systolic blood pressure: review of clinical trial data.
Hall WD. Hall WD. Am Heart J. 1999 Sep;138(3 Pt 2):225-30. doi: 10.1016/s0002-8703(99)70314-5. Am Heart J. 1999. PMID: 10467217 Review. - [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S, Bakir SE. Oparil S, et al. Drugs. 2000;59 Spec No 2:25-37. Drugs. 2000. PMID: 11002856 Review. French.
Cited by
- Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia.
Cunningham EL, Todd SA, Passmore P, Bullock R, McGuinness B. Cunningham EL, et al. Cochrane Database Syst Rev. 2021 May 24;5(5):CD004034. doi: 10.1002/14651858.CD004034.pub4. Cochrane Database Syst Rev. 2021. PMID: 34028812 Free PMC article. - Recent outcome trials of newer antihypertensives.
Bakir S, Oparil S. Bakir S, et al. Curr Hypertens Rep. 1999 Jun;1(3):238-40. doi: 10.1007/s11906-999-0027-4. Curr Hypertens Rep. 1999. PMID: 10981072 No abstract available. - Clinical trials in isolated systolic hypertension.
Gasowski J, Wang JG, Staessen JA. Gasowski J, et al. Curr Hypertens Rep. 1999 Oct;1(5):387-93. doi: 10.1007/s11906-999-0053-2. Curr Hypertens Rep. 1999. PMID: 10981095 - Prognostic significance of blood pressure in the very old. Implications for the treatment decision.
Bulpitt CJ, Fletcher AE. Bulpitt CJ, et al. Drugs Aging. 1994 Sep;5(3):184-91. doi: 10.2165/00002512-199405030-00004. Drugs Aging. 1994. PMID: 7803946 Review. - Calcium channel blockers versus other classes of drugs for hypertension.
Zhu J, Chen N, Zhou M, Guo J, Zhu C, Zhou J, Ma M, He L. Zhu J, et al. Cochrane Database Syst Rev. 2021 Oct 17;10(10):CD003654. doi: 10.1002/14651858.CD003654.pub5. Cochrane Database Syst Rev. 2021. PMID: 34657281 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical